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Forty-eight patients were subdivided according to C-reactive protein (CRP) levels, resulting in 19 patients with normal (2.8 ±
2.8mg/L) and 29 with elevated (82.2 ± 76.2mg/L) CRP levels. The elevated CRP group had iron and red blood cell (RBC)
proﬁles characteristic of chronic immune stimulation (CIS), and the normal CRP group, proﬁles of true iron deﬁciency. Normal
relationships between storage iron, bioavailable iron, and RBC indices were absent in the elevated CRP group—implying the role
of iron as major determinant of the RBC proﬁle to be diminished during CIS. The elevated CRP group had signiﬁcant increases
in proinﬂammatory cytokines (INF-γ,T N F - α,I l - 1 β, Il-6, and Il-8). Anti-inﬂammatory cytokine levels were normal, except for
Il-10, supporting previous indications that Il-10 contributes to reducing bioavailable iron. Regression analysis suggested decreases
in transferrin to be related to increases in Il-8 and an increase in ferritin to be related to a decrease in Il-12 levels. TGF-β levels were
positively related to transferrin and negatively to ferritin.
1.Introduction
Cytokine production is a feature of immune stimulation,
and alterations in the cytokine proﬁle can inﬂuence both
the iron status and red blood cell proﬁle. Chronic immune
stimulation is often associated with a decrease in serum
iron. Depending on the cause of the immune stimulation,
the purpose of this decrease is to reduce the bioavailability
of iron in order to stem uncontrolled cellular proliferation,
to reduce excessive production of reactive oxygen radicals
and/or to withhold iron from pathogenic microorganisms.
The eﬀects of cytokines on iron bioavailability are largely
mediated through a reduction in duodenal absorption of
iron and a shift in the handling of iron by the macrophage
in favour of iron storage. The latter can, in time, lead to
hypoferraemia [1–3] and haemosiderosis of the macrophage
[2, 4, 5]. This reduction in bioavailable iron can contribute
to the anaemia of chronic disease (ACD).
It is commonly accepted that duodenal absorption of
iron is decreased during chronic immune stimulation [6],
and that cytokines are involved [7]. Under normal condi-
tions, absorbed Fe2+ joins the intracellular labile iron pool of
the enterocyte from where it can either be stored in the iron
storage protein, ferritin, of the enterocyte, or translocated to
the basolateral membrane for transport into the circulation
[8, 9]. With chronic immune stimulation the expression
of enterocyte ferritin is upregulated, resulting in excessive
sequestration and entrapment of iron within the enterocyte
[10]. This newly acquired enterocyte iron will subsequently
be expelled from the body during sloughing of the lining
of the gastrointestinal tract. In addition, the numbers of
the basolateral membrane iron exporter, ferroportin, are
reduced thus blocking the entry of absorbed iron into the
circulation. Ferroportin expression is downregulated by the
acute phase protein, hepcidin. Hepcidin release is stimulated
by the cytokine interleukin-6 [11].2 Mediators of Inﬂammation
Iron circulates between the iron-containing compart-
ments (intercellular iron shuttling) bound to the plasma
iron transport protein transferrin. Transferrin is a negative
acutephase protein, andassuchserumtransferrinis reduced
during immune stimulation [6] resulting in less iron being
available for cellular processes. Although interleukin-6 is the
major cytokine responsible for the regulation of acute phase
protein synthesis during chronic immune stimulation [12],
other cytokines, including interleukin-1β, tumor necrosis
factor-α, and interleukin-8, have also been found to moder-
ately inﬂuence the synthesis of acute phase proteins [12–14].
Ferritin, the major intracellular protein responsible for
t h es t o r a g eo fm a c r o p h a g ei r o n ,p l a y sam a j o rr o l ei n
the establishment and maintenance of an iron transfer
block in the macrophage and thus in the hypoferraemic
state of chronic immune stimulation. Ferritin up-regulation
precedes the reduction in serum iron [15]. The proin-
ﬂammatory cytokines tumor necrosis factor-α, interleukin-
1β, interleukin-6, and the anti-inﬂammatory cytokine
interleukin-10 have all been shown to directly stimulate the
transcription and translation of ferritin [16–18]. Cytokines
notonlyupregulateferritinexpression,butalsostimulatethe
macrophage to increase its uptake of iron by increasing the
expression of the divalent metal transporter 1. Interferon-γ
has been shown to stimulate the uptake of ferrous iron by
macrophages. In addition, the anti-inﬂammatory cytokines,
interleukin-4 and interleukin-10, can upregulate transferrin
receptor expression, resulting in an increase in transferrin
receptor-mediated uptake of iron by the macrophage [6, 18].
The macrophage obtains most of its iron by the degrada-
tion of haemoglobin and phagocytosis, and degradation of
senescent erythrocytes is known to increase during chronic
immune stimulation. This process is directly upregulated
by tumor necrosis factor-α that stimulates the expression
ofC3bi(CD11b/CD18) receptors—thereceptorsresponsible
for the recognition and uptake of damaged erythrocytes.
In addition, tumor necrosis factor-α can also indirectly
upregulatethisprocessbydamagingcirculatingerythrocytes.
These damaged erythrocytes are then phagocytosed upon
binding to C3bi (CD11b/CD18) receptors [6, 18]. Not
only is haemoglobin iron obtained by degradation of red
blood cells, but free plasma haemoglobin is taken up by
the haemoglobin scavenger receptor, CD163. Interleukin-
10 and interleukin-6 augment macrophage haemoglobin
acquisitionbystimulatingtheexpressionofthehaemoglobin
scavenger receptor, CD163 [18]. In addition to increased
uptake of iron by the macrophage during immune stimula-
tion, release of iron is also reduced. Interferon-γ contributes
to this by downregulating the expression of ferroportin, the
major transmembrane protein responsible for the release of
macrophage iron [18]—a process that is also aﬀected by
hepcidin [19]. Many proinﬂammatory mediated eﬀects on
iron homeostasis are counterbalanced by anti-inﬂammatory
cytokines such as interleukin-4 and interleukin-13 [18].
Theaimofthisstudywastoinvestigatethepro-andanti-
inﬂammatorycytokinestatusandthepossiblerelationshipof
thesecytokinestotheironstatusandredbloodcellproﬁlesin
patients with chronic immune stimulation. A diverse group
of patients with chronic disease was divided into two groups
based on their C-reactive protein levels and then evaluated
in terms of their iron status, red blood cell proﬁles, and pro-
and anti-inﬂammatory cytokines.
2.MaterialsandMethods
2.1. Patients. The study group consisted of 48 patients
attending the Department of Internal Medicine, Kalafong
Hospital, South Africa, for treatment of chronic diseases.
Blood and bone marrow were collected from each patient.
The diagnosis of the patients were diverse and included vari-
ous types of infections (tuberculosis (TB), malaria, human
immunodeﬁciency virus (HIV)), cancers (lung, breast),
pancytopenias as a result of bone marrow suppression or
peripheraldestructionofbloodcells,organfailuresincluding
renal failure, heart failure and liver failure, anaemias with
diﬀerent etiologies, and various other pathologies. This
resulted in an extremely heterogenous group of patients.
The diagnosis and HIV status of all patients are presented
in Table 1. Patients were subdivided based on their C-
reactive protein levels. Ethical clearance for the study was
obtained from the Faculty of Health Sciences Research Ethics
Committee, University of Pretoria (ethical clearance number
118/2003), and all patients gave informed consent.
2.2. C-Reactive Protein (CRP). CRP levels were determined
by a CRP ELISA (DRG Diagnostics, Germany, Orb Diagnos-
tics, Modderfontein, South Africa).
2.3. Cytokines. Interleukin-8 (Il-8), interleukin-1β (Il-1β),
interleukin-6 (Il-6), interleukin-10 (Il-10), tumor necrosis
factor-α (TNF-α), and interleukin-12p70 (Il-12) were deter-
mined by the Human Inﬂammation Kit, BD Cytometric
Bead Array (CBA) (The Scientiﬁc group, Midrand, South
Africa).Interleukin-2(Il-2),interleukin-4(Il-4),interleukin-
5 (Il-5), interleukin-10 (Il-10), tumor necrosis factor-α
(TNF-α), and interferon-γ (INF-γ) were determined by the
BD Cytometric Human T-helper cell type-1/T-helper cell
type-2 Cytokine Kit (The Scientiﬁc group, Midrand, South
Africa). With the T-helper cell type-1/T-helper cell type-2
CBA cytokine kit, the interferon-γ standards were lost and
the measurement of INF-γ was done by the human INF-γ
ELISA Kit, BD OptEIA test (The Scientiﬁc group, Midrand,
South Africa). Il-10 and TNF-α were measured in both the
Human Inﬂammation kit and the Human T-helper cell type-
1/T-helper cell type-2 kit. The mean of these values were
calculated and used for statistical analysis. Transforming
growth factor-β1( T G F - β1) was determined by a TGF-β1
ELISA (DRG Diagnostics, Germany, Orb Diagnostics, Mod-
derfontein, South Africa). Granulocyte macrophage-colony
stimulating factor (GM-CSF) was determined by a GM-
CSF ELISA (DRG Diagnostics, Germany, Orb Diagnostics,
Modderfontein, South Africa).
2.4. Serum Iron Markers. Serum iron markers were deter-
mined by the Chemical Pathology laboratory, National
Health Laboratory Services (NHLS), University of Pretoria,
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2.5. Soluble Transferrin Receptor. The soluble transferrin
receptor was determined by an ELISA from Ramco Labora-
tories, Inc., Texas, USA.
2.6. Prussian Blue Iron Stains of Bone Marrow Aspirates and
Core Bone Marrow Biopsies
2.6.1. HCl-Ferrocyanide Iron Stains of Bone Marrow Aspirate
Smears. The iron stains and evaluation of the bone marrow
aspirate smears were performed by the Haematology labora-
tory, NHLS, University of Pretoria, South Africa.
2.6.2. HCl-Ferrocyanide Iron Stains of Core Bone Marrow LR
White Plastic Sections. A piece of core bone marrow was
obtained during the time the patients had their biopsies,
taken for diagnostic purposes, and placed immediately in the
ﬁxative on ice. The ﬁxative consisted of 4% formaldehyde
(FA) and 0.05% glutaraldehyde (GA) in a 0.15M sodium
phosphate buﬀer. The ﬁxative was prepared fresh immedi-
ately prior to the obtainment of bone marrow tissue. A 10%
paraformaldehyde solution in deionised H2O was prepared
fresh in a fume hood (Paraformaldehyde (Trioxymethylene),
SPI Supplies, cat. no. 2615, Rick Loveland & Associates,
Halfway House, South Africa). The solution was heated
to 60–70◦C with constant stirring. Once the solution had
reached the proper temperature stirring was continued for
15 minutes. At this point, the solution was milky. One to
two drops of 1N NaOH was added, with stirring, until the
solution cleared [20]. The 0.15M sodium phosphate buﬀer
was prepared from two stock solutions, a 0.3M Na2HPO4
stock solution (di-Sodium hydrogen phosphate Dihydrate,
Fluka, BioChemika, Ultra, cat. no. 71643, Sigma-Aldrich,
Aston Manor, South Africa) and a 0.3M NaH2PO4 stock
solution (Sodium dihydrogen phosphate Dihydrate, Fluka,
Biochemika, MicroSelect, cat. no. 71505, Sigma-Aldrich,
Aston Manor, South Africa). The 0.3M NaH2PO4 stock
solution was added to the 0.3M Na2HPO4 stock solution
to a pH of 7.25 immediately prior to the obtainment of
bone marrow tissue. This 0.3M sodium phosphate buﬀer
solution was then diluted 1:1 with the 10% freshly prepared
formaldehyde stock solution and deionised H2O. This was
followed by the addition of the GA (Pure Glutaraldehyde
25% solution, E.M. grade, SPI Supplies, cat. no. 2607, Rick
Loveland & Associates, Halfway House, South Africa). The
bone marrow tissue was ﬁxed for 24 hours at 6◦C in this
ﬁxative. All subsequent steps were carried out at 6◦Cw i t h
rotation(TAABrotator,WirsamScientiﬁc,Richmond,South
Africa). After 24 hours, the bone marrow tissue was washed
3 times for 20 minutes with the sodium phosphate buﬀer. It
was then dehydrated as follows: 50% EtOH, 70% EtOH, 30
minutes each, followed by 85% EtOH, twice for 15 minutes
each (Ethanol 99.9% Absolute A.R., Minema, Rick Loveland
& Associates, Halfway House, South Africa). Subsequently,
the bone marrow tissue was inﬁltrated with a 1:1 85%
EtOH:LRWhitemixturefor30minutes.LRWhitedissolved
in 85% EtOH but not in 80% EtOH (LR White Resin,
medium grade acrylic resin, London Resin Company LTD.,
Rick Loveland & Associates, Halfway House, South Africa).
The bone marrow tissue was inﬁltrated with LR White,
twice for 30 minutes each. The tissue was then placed in
gelatine capsules in fresh LR White ensuring no air bubbles
and polymerised for 24 hours at 50◦C (Gelatine capsules,
SPI Supplies, cat. no. 2302, Rick Loveland & Associates,
Halfway House, South Africa). The block of bone marrow
tissuewassectionedinto2μmthicksectionswhichwerethen
placed on microscope slides (Menzel-Glaser Superfrost Plus
Microscope Slides, Labotec, Halfway House, South Africa).
The slides were rinsed in deionised H2O before the staining
procedure. The sections were stained for 1 hour in 10%
ferrocyanide/10%HClpreparedjustbeforeuseinCoplinjars
at 25◦C (10% ferrocyanide, Potassium hexacyanoferrate (II)
Trihydrate, Fluka, Biochemika Ultra, cat. no. 60279, Sigma-
Aldrich, Aston Manor, South Africa; 10% HCl, Hydrochloric
acid 30%, Riedel-de-Ha¨ en, cat. no. 30053, Sigma-Aldrich,
Aston Manor, South Africa). After the staining step, the
slides were rinsed in deionised H2O .T h es e c t i o n sw e r e
counterstained with 1% eosin in 70% ethanol (acidiﬁed) for
10 minutes (1% eosin, Eosin yellowish, Gurr, Microscopy
Material, cat. no. 45380, BDH Chemicals Ltd., England, in
70% ethanol, acidiﬁed with acetic acid). Once again, the
slides were rinsed in deionised H2O. Finally, the slides were
air-driedonahotplateandmountedwithimmersionoiland
a cover slide.
2.7. Red Blood Cell Proﬁle. Red blood cell counts, haemo-
globin concentration, mean corpuscular volume (MCV),
mean corpuscular haemoglobin (MCH), mean corpuscular
haemoglobin concentration (MCHC), and red blood cell
distribution width (RDW) were determined by the NHLS,
University of Pretoria, South Africa.
2.8. Statistical Analysis. The ranksum test was employed on
log transformed data. This was done due to the skewness of
the data sets. For summary statistics, the geometric mean
and the 95% conﬁdence interval were reported. Pearson’s
product-moment correlation coeﬃcient (r)w a se m p l o y e d
to assess dependence between study parameters. Testing was
done at the 0.05 level of signiﬁcance. Forward stepwise
regression with pe = 0.2 as the entrance point was employed
to investigate the relationship between each of the iron status
and red blood cell proﬁle parameters and the pro- and anti-
inﬂammatory cytokines. pe speciﬁes the signiﬁcance level for
addition to the model; thus, terms with P<. 2 are eligible for
addition. The discrepancy between R2 and adjusted R2 was
d u et ot h es m a l ls a m p l es i z e .
3. Results
The patients were subdivided according to the immunolog-
ical indicator C-reactive protein into a group with normal
(≤10mg/L)andagroupwithelevated(>10mg/L)C-reactive
protein levels. This resulted in a group of 19 patients with
normalC-reactiveprotein(2.8 ±2.8mg/L)andagroupof29
patients with elevated C-reactive protein (82.2 ± 76.2mg/L).
The average and SD for age for the group of patients with
elevated C-reactive protein was 41.6 ± 15.9 years and for the4 Mediators of Inﬂammation
group of patients with normal C-reactive protein 42.3 ± 15.2
years. The majority of patients were black females, with the
exception of four males and three whites and six males and
one white in the elevated C-reactive protein and normal C-
reactive protein groups, respectively.
The results for the pro- and anti-inﬂammatory cytokines
are presented in Table 2. Various proinﬂammatory cytokines
including INF-γ,T N F - α, Il-1β, Il-6, and Il-8 were ele-
vated in the group of patients with elevated C-reactive
protein compared to the group of patients with normal
C-reactive protein. No signiﬁcant diﬀerences were shown
for the proinﬂammatory cytokines Il-2 and Il-12. The T-
helper cell type-2 cytokines involved in predominantly anti-
inﬂammatory processes including Il-4, Il-5 and TGF-β,w e r e
not signiﬁcantly diﬀerent between the group of patients with
elevated C-reactive protein and the group of patients with
normal C-reactive protein. However, the T-helper cell type-
2 cytokine, Il-10, was signiﬁcantly higher in the group of
patients with elevated C-reactive protein compared to the
group of patients with normal C-reactive protein.
The iron status of the group of patients with elevated C-
reactive protein was characteristic of patients with a chronic
proinﬂammatory immune status. The serum iron markers
and soluble transferrin receptor for the two groups of
patients are shown in Table 3. Serum transferrin levels were
signiﬁcantly lower, serum ferritin signiﬁcantly higher, and
soluble transferrin receptor signiﬁcantly lower in the group
with elevated C-reactive protein.
When the red blood cell proﬁles of the group with
normal C-reactive protein and the group with elevated C-
reactive protein were compared (Table 4), it was seen that
both groups were anaemic, but that the MCV, MCH, and
the MCHC were signiﬁcantly lower in the group of patients
with normal C-reactive protein. The RDW did not diﬀer
signiﬁcantlybetweenthegroups,butwashigherthannormal
for both groups.
To assess total body iron stores, in order to distinguish
b e t w e e nt r u ei r o nd e ﬁ c i e n c ya n da ni r o nt r a n s f e rb l o c k ,a
Prussian blue iron stain was performed on the bone marrow
aspirates and bone marrow cores. Results can be seen in
Table 5.
Various correlations were shown between storage iron,
bioavailable iron, and red blood cell production in the group
of patients with normal C-reactive protein. None of these
correlations could be demonstrated in the group of patients
with elevated C-reactive protein (refer to Table 6).
The dependence of various serum iron markers, soluble
transferrin receptor, and red blood cell indices on pro- and
anti-inﬂammatory cytokines in the group of patients with
elevated C-reactive protein are presented in Table 7.
4. Discussion
C-reactive protein is an acute phase protein and rises sharply
withtheonsetofinﬂammationreachingpeakconcentrations
within 24–48 hours. Inﬂammatory processes accompanying
tissue injury, infection, malignancy, autoimmune diseases,
and cardiovascular diseases can all result in an increase in C-
reactive protein levels [21]. C-reactive protein is synthesised
and secreted by hepatocytes upon stimulation by acute phase
protein-inducing cytokines such as Il-6 [22]. In patients
with elevated C-reactive protein, the macrophage takes on
a proinﬂammatory role, which is characteristic of a T-helper
cell type-1 immune response. An increase in C-reactive
protein is thus seen as an indicator of the involvement
of the classically activated macrophage (proinﬂammatory
macrophage). C-reactive protein levels are considered by
some as the most accurate reﬂection of the inﬂammatory
state [23].
In the present study, patients with chronic disease were
divided into two groups based on their C-reactive protein
levels and then evaluated in terms of their iron status,
red blood cell proﬁles, and pro- and anti-inﬂammatory
cytokines.
Iron status was evaluated by Prussian blue iron stains
of bone marrow aspirates and cores, by levels of serum
iron markers, and by red blood cell indices. The results are
shown in Tables 3, 4,a n d5. In the group of patients with
high C-reactive protein levels, a high prevalence of iron
transfer block was found when all factors were considered.
The prevalence was 69% for the patients with elevated
C-reactive protein, in contrast to the 26% for the group
with normal C-reactive protein levels. The majority of the
patients with high C-reactive protein levels had serum iron
proﬁles characteristic of patients with an iron transfer block
[6], that is, a decrease in serum iron, an increase in ferritin, a
decrease in transferrin, a small increase in soluble transferrin
receptor, a decrease in transferrin/log ferritin ratio, and a
decrease in soluble transferrin receptor/log ferritin ratio. As
was expected, most of the patients with normal C-reactive
protein did not have serum iron proﬁles characteristic
of an iron transfer block. However, these patients had a
high incidence of true iron deﬁciency. For these patients, a
decreased serum iron, normal ferritin, normal transferrin, a
marked increase in soluble transferrin receptor, an increase
in transferrin/log ferritin ratio, and an increase in the soluble
transferrin receptor/log ferritin ratio were shown.
Chronic immune stimulation has a negative eﬀect on
red blood cell production. Immune-stimulated decreases
in bioavailable iron contribute, but other factors, mostly
cytokine-induced, are also involved. Such factors include
suppression of the proliferation of erythroid progenitor cells,
adecreaseinthesynthesisoferythropoietin,adecreaseinthe
sensitivity of erythroblasts to erythropoietin, and shortened
red blood cell life span [24–26]. The anaemia of chronic
disease is, therefore, on the one hand, the result of a decrease
in iron reaching the erythron and, on the other, that of a
suppression of red blood cell synthesis [24–26].
In this study, anaemia was present in the majority of
patients, irrespective of their C-reactive protein levels. In the
patients with normal C-reactive protein the inclusion of a
couple of patients with diﬀerent red blood cell pathologies,
such as macrocytic anaemia, resulted in a normal mean cor-
puscular volume for the group. However, both the mean cor-
puscular haemoglobin and mean corpuscular haemoglobin
concentration were decreased, which is characteristic of the
anaemia of true iron deﬁciency. In the patients with elevated
C-reactive protein, the average for the mean corpuscularMediators of Inﬂammation 5
Table 1: Diagnosis and HIV status of the patients (∗elevated CRP).
Patient Diagnosis HIV
1∗ Pneumonia and sepsis, Escherichia coli and urinary tract infection and acute renal failure pos
2∗ Heart failure and megaloblastic anaemia and pernicious neg
3∗ Anaemia and idiopathic thrombocytic purpura and acute haemolytic anaemia versus disseminated
intravascular coagulopathy, post mortem pos
4∗ Carcinoid cancer and pneumonia and metastasis to the brain neg
5∗ Idiopathic vasculitis and pancytopenia questioning antiphospholipid syndrome and uterine mass neg
6 Malaria and idiopathic thrombocytic purpura neg
7∗ Cruveilhier-Baumgarten disease and hypersplenism and TB neg
8∗ Lung cancer and acute renal failure and pneumonia neg
9∗ Pneumonia, Escherichia coli pos
10 Idiopathic thrombocytic purpura and iron deﬁcient anaemia and questioning systemic lupus erythematosus neg
11∗ Retroviral disease and renal failure pos
12 Metastatic breast cancer neg
13∗ Pneumonia and confusion pos
14∗ Pulmonary TB and eﬀusion pos
15 Megaloblastic anaemia neg
16 Anaemia due to blood loss neg
17 Retroviral disease and anaemia and Kaposi’s sarcoma and previous pulmonary TB pos
18∗ Antiphospholipid syndrome and haemolytic anaemia neg
19∗ Retroviral disease and bicytopenia and mycobacterium avium complex pos
20∗ Retroviral disease and anaemia and dilated cardiomyopathy and antiphospholipid syndrome and TB and
thrombosis pos
21∗ Retroviral disease and TB and sepsis and anaemia and ascitis pos
22∗ Chronic obstructive pulmonary disease and liver and kidney failure and pelagra and sepsis and ethanol abuse neg
23∗ Retroviral disease and pneumonia and pancytopenia pos
24 Idiopathic thrombocytic purpura neg
25 Retroviral disease and diabetes mellitus and heart failure and obesity and splenomegaly and lymphadenopathy
and TB, bone marrow pos
26∗ Ethanol abuse and radial fracture and pulmonary TB and bradycardia and primary hypertension, increase
calcium neg
27 Massive splenomegaly and pancytopenia neg
28∗ Megaloblastic anaemia and syphilis neg
29∗ Delerium and TB and calciﬁed nodes, post mortem = miliary TB neg
30∗ OD and thrombocytopenia and macrocytosis and ethanol abuse neg
31∗ Retroviral disease and pulmonary TB and pancytopenia pos
32 Nephritis: hypertension, edema, proteinuria neg
33∗ Pancytopenia and ascitis and TB and proteinuria and urinary tract infection and sepsis, ICU neg
34∗ Retroviral disease and Hodgkin’s disease and TB pos
35 Hypertension and diabetes mellitus and leucocytosis, persistent neg
36∗ Retroviral disease on HAART and pulmonary TB pos
37 Retroviral disease and idiopathic thrombocytic purpura-immune, normal spleen pos
38 Megaloblastic anaemia and hypothyroidism neg
39 Anaemia neg
40∗ Anaemia and pyrexia and miliary TB, bone marrow culture pos
41 Pancytopenia and idiopathic thrombocytic purpura pos
42 Iron-deﬁcient anaemia neg
43 Iron-deﬁcient anaemia and peptic ulcer disease and pneumonia, Staphylococcus aureus neg
44∗ Idiopathic 4-limb African gangrene neg
45 Retroviral disease and pneumonia and pancytopenia pos6 Mediators of Inﬂammation
Table 1: Continued.
Patient Diagnosis HIV
46∗ Monoclonal gammopathy of undetermined signiﬁcance and uterine mass neg
47∗ Retroviral disease and pancytopenia and pneumonia pos
48 Idiopathic thrombocytic purpura and bicytopenia neg
Table 2: Cytokine levels for patients with elevated C-reactive
protein and patients with normal C-reactive protein.
Elevated CRP
(n = 28)
Geometric mean;
95% conﬁdence
interval
Normal CRP
(n = 19)
Geometric mean;
95% conﬁdence
interval
P-value
INF-γ 2.00;
0.76–5.27
0.18;
0.09–0.37 .001
TNF-α 3.47;
2.78–4.32
2.29;
1.88–2.78 .009
Il-1β 1.81;
0.92–3.57
0.49;
0.26–0.92 .008
Il-6 79.23;
36.69–171.09
3.56;
2.08–6.09 .000
Il-12 2.69;
1.69–4.28
2.73;
1.50–4.99 .97
Il-2 7.41;
4.85–11.33
5.04;
2.45–10.37 .31
Il-8 88.12;
49.84–155.80
14.20;
8.80–22.91 .000
GM-CSF 2.15;
1.21–3.81
2.58;
0.89–7.44 .73
Il-4 1.74;
1.21–2.51
1.48;
0.87–2.50 .59
Il-5 2.35;
1.74–3.16
2.23;
1.18–4.19 .86
TGF-β 10.51;
8.34–13.24
8.60;
6.34–11.67 .28
Il-10 9.37;
5.66–15.51
4.56;
3.29–6.32 .034
volume corresponded to that of a normocytic red blood cell
proﬁle. It is known that patients with the anaemia of chronic
disease (ACD) often exhibit a normocytic, normochromic
anaemia when they are initially seen in medical care facilities
[6, 27]. With further development of ACD, these patients
develop a microcytic, hypochromic anaemia. In view of
the iron status of the two groups, it would be reasonable
to assume that the group with normal C-reactive protein
had true iron deﬁciency anaemia, while the anaemia of the
high C-reactive protein group was predominantly that of
chronic disease. Il-1β,T N F - α,a n dT G F - β have been shown
to inhibit erythropoietin synthesis and action [28]. In the
present study, there were, as will be discussed later, increases
in Il-1β and TNF-α levels in the group of patients with high
C-reactive protein levels.
An important diﬀerence with regard to the relationship
between iron availability and the red blood cell proﬁle was
observed between the group with elevated C-reactive protein
levels and that with normal levels. The normal expected
relationships were found in the group with normal C-
reactive protein levels. For instance, the correlations between
transferrin saturation and MCV (0.62, 0.005), transferrin
saturationandMCH(0.64,0.003),andtransferrinsaturation
and MCHC (0.49, 0.033) supported the notion that an
increase in the availability of iron has a positive eﬀect on the
red blood cell proﬁle [29–31]. The negative correlations seen
b e t w e e ns e r u mt r a n s f e r r i na n dM C V( −0.62, 0.005), serum
transferrinandMCH(−0.74, 0.0003), and serumtransferrin
and MCHC (−0.79, 0.001) reﬂected the fact that an increase
in serum transferrin, related to iron-deﬁcient iron stores,
generally results in iron-deﬁcient erythropoiesis [29–31].
In addition, the following negative correlations, between
solubletransferrinreceptorandMCV(−0.65,0.002),soluble
transferrin receptor and MCH (−0.75, 0.0002), and soluble
transferrin receptor and MCHC (−0.75, 0.0002) demon-
strated the increase in soluble transferrin receptor levels
normally found with deﬁcient red blood cell production
[31]. These normal relationships did not exist in the high C-
reactiveproteingroup(Table 6).Theresultsofthisstudythus
conﬁrm bioavailability of iron to be a major determinant
of the red blood cell proﬁle. However, with pronounced
proinﬂammatory activity (signiﬁcantly elevated C-reactive
protein), accompanied by an iron transfer block and ACD,
this dominancy of bioavailable iron in the regulation of
proper red blood cell production was lost.
In this study, results on the cytokine proﬁles supported
the subdivision into a normal and a proinﬂammatory group
on the basis of C-reactive protein levels. Most of the
proinﬂammatory cytokines, including INF-γ,T N F - α, Il-1β,
Il-6, and Il-8, were signiﬁcantly higher in the group of
patients with elevated C-reactive protein compared to the
group of patients with normal C-reactive protein. These
cytokines are known to play a role in the reduction of
available iron during chronic immune stimulation. INF-γ
has,forinstance,beenshowntodownregulatetheexpression
of the transmembrane protein ferroportin [18]. Il-1β,T N F -
α, and Il-6 have been reported to directly stimulate the
transcription and translation of ferritin [16, 17], while Il-1β,
TNF-α, Il-6, and Il-8 stimulation are known to contribute
to the synthesis of acute phase proteins [12–14]. Further-
more, TNF-α, has been shown to increase the acquisition
of erythrocyte iron by the macrophage by increasing the
expression of C3bi (CD11b/CD18) receptors [6, 18]. Il-
6, in addition to its role as major cytokine responsible
for the regulation of acute phase protein synthesis [12],Mediators of Inﬂammation 7
Table 3: Serum iron markers and soluble transferrin receptor for patients with elevated C-reactive protein and patients with normal C-
reactive protein.
Normal laboratory values
Elevated CRP (n = 28)
Geometric mean;
95% conﬁdence interval
Normal CRP (n = 19)
Geometric mean;
95% conﬁdence interval
P-value
Serum iron
(10–30μmol/L)
6.87;
5.11–9.22
7.89;
5.15–12.08 .57
Serum transferrin
(2–3.6g/L)
1.21;
1.04–1.41
2.33;
1.98–2.75 .000
Transferrin saturation
(15–50% f, 20–50% m)
21.59;
14.90–31.26
14.34;
8.48–24.25 .18
Serum ferritin
(11–306.8μg/L f,
23.9–336.2μg/L m)
928.70;
482.12–1788.95
44.97;
19.31–104.71 .000
Transferrin/log ferritin 0.43;
0.34–0.54
1.59;
1.07–2.38 .000
Soluble transferrin receptor
(2.9–8.3μg/mL)
7.41;
5.69–9.67
13.38;
9.30–19.24 .008
Soluble transferrin
receptor/log ferritin
2.58;
1.94–3.43
9.14;
5.22–16.00 .000
Table 4: Red blood cell indices for patients with elevated C-reactive protein and patients with normal C-reactive protein.
Normal laboratory values
Elevated CRP (n = 28)
Geometric mean;
95% conﬁdence interval
Normal CRP (n = 19)
Geometric mean;
95% conﬁdence interval
P-value
Red blood cell count
(4.13–5.67 × 1012/L f, 4.89–6.11 × 1012/L m)
2.33;
1.95–2.78
2.62;
2.04–3.36 .42
Haemoglobin
(12.1–16.3 g/dL f, 14.3–18.3 g/dL m)
6.80;
5.66–8.16
6.23;
4.74–8.19 .57
Haematocrit
(0.370–0.490L/L f, 0.430–0.550L/L m)
0.21;
0.18–0.25
0.21;
0.16–0.27 .94
Mean corpuscular volume
(79.1–98.9 fL)
90.05;
84.42–96.05
78.98;
72.01–86.62 .016
Mean corpuscular haemoglobin
(27–32pg)
29.24;
27.09–31.55
23.82;
21.13–26.84 .003
Mean corpuscular haemoglobin
concentration (32–36g/dL)
32.47;
31.70–33.26
30.16;
29.00–31.38 .001
Red blood cell distribution width
(11.6–14%)
19.39;
17.48–21.51
21.34;
18.38–24.77 .27
Table 5: Iron stores and prevalence of iron transfer block for
patients with elevated C-reactive protein and patients with normal
C-reactive protein.
Elevated C-reactive
protein
n = 29
Normal C-reactive
protein
n = 19
Increased iron stores 59% 16%
Normal iron stores 22% 21%
Decreased iron stores 19% 63%
Iron transfer block 69% 26%
No iron transfer block 31% 74%
also stimulates the release of hepcidin [11], as well as the
expression of the haemoglobin scavenger receptor, CD163
[18]. The proinﬂammatory cytokine results of this study are,
therefore, in line with previous ﬁndings.
The only proinﬂammatory cytokines that were not
signiﬁcantly higher in the group of patients with elevated
C-reactive protein were Il-2 and Il-12. This may perhaps be
explained by the inclusion of many HIV-positive patients (15
of29patients)inthisgroup.Withhumanimmunodeﬁciency
virus infection, the production of both Il-2 and Il-12 are
reduced [32, 33].
The T-helper cell type-2 cytokines, Il-4, Il-5 and TGF-
β, were not signiﬁcantly diﬀerent between the patients with8 Mediators of Inﬂammation
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elevated C-reactive protein and the patients with normal
C-reactive protein. However, Il-10, was signiﬁcantly higher
in the group with elevated C-reactive protein. This ﬁnding
is in agreement with previous indications that the anti-
inﬂammatory cytokine interleukin-10 can contribute to
the hypoferraemia of chronic immune stimulation by up-
regulating the transcription and translation of ferritin and
by stimulating the expression of the haemoglobin scavenger
receptor, CD163 [6, 18].
The above results supported the notion that T-helper
cell type-1/proinﬂammatory cytokines are the major role
players in the development of an iron transfer block.
However, indications such as the raised levels of Il-10 and
the observation that the iron transfer block was also seen in
a number of patients with normal C-reactive protein levels,
supportprevioussuggestions[6,18]thatT-helpercelltype-2
cytokines also play a role in the development/maintenance of
an iron transfer block.
Regression analysis showed both serum transferrin and
serum ferritin to be highly associated with the levels of a
number of cytokines. For the proinﬂammatory cytokine, Il-
8, there was a signiﬁcant association with serum transferrin,
with an increase in Il-8 related to a reduction in transferrin.
This is in line with the assumed roles of the proinﬂammatory
cytokines in bringing about a decrease in serum transferrin
during chronic immune responses. For the proinﬂammatory
cytokine, Il-12, there was a signiﬁcant association with
serum ferritin, with an increase in ferritin related to a
decrease in Il-12. This might be explained by the possible
immunosuppressive role of ferritin in HIV/AIDS [34]. In
the present study, no signiﬁcant diﬀerence were found
for TGF-β levels between the patients with elevated C-
reactive protein and patients with normal C-reactive protein.
However, in the patients with elevated C-reactive protein
it was shown that both transferrin and ferritin levels were
related to TGF-β levels. TGF-β levels were positively related
to transferrin levels and negatively to ferritin levels. This
may perhaps suggest TGF-β to play a role in control of the
proinﬂammatory response.
5. Conclusions
Patients with elevated C-reactive protein levels have a
predominantly proinﬂammatory cytokine proﬁle. C-reactive
proteinlevelsarethusagoodgeneralreﬂectionofproinﬂam-
matorystatus.Themajority,butnotall,ofpatientswithhigh
C-reactive protein have an iron transfer block. The results
support previous indications that, during chronic immune
stimulation, the anti-inﬂammatory cytokine, Il-10, con-
tributes to reducing bioavailable iron. The proinﬂammatory
cytokine Il-8 might be involved in decreasing of transferrin.
Ferritin, as an immunosuppressive agent, may play a role in
the decrease of Il-12 production. TGF-β appears to play a
role in the control of the proinﬂammatory response. During
overt proinﬂammatory conditions the normal relationships
between storage iron, bioavailable iron, and red blood cell
indices are disrupted and iron bioavailability may lose its
role as major determinant of the red blood cell proﬁle. The
latter ﬁnding has implications for the administration of iron
to patients with ACD.
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